The true costs of administering infliximab to patients with Crohn's disease (CD) are likely to be lower in clinical practice than those reported for charged amounts

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.521, 2007-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Managing Immunogenic Responses to Infliximab: Treatment Implications for Patients with Crohn’s Disease

By Peter D. Han   Russell D. Cohen  

Drugs, Vol. 64, Iss. 16, 2004-01 ,pp. : 1767-1777

Adis International

Access to resources Recommend Favorite

Infliximab promising in paediatric Crohn's disease

By  

Inpharma, Vol. 1, Iss. 1391, 2003-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Infliximab: additional benefits in Crohn's disease

By  

Inpharma, Vol. 1, Iss. 1349, 2002-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Infliximab worth it for Crohn's disease in the UK

By  

Inpharma, Vol. 1, Iss. 1515, 2005-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Infliximab: First reports of colorectal cancer in patients with Crohn's disease (one in an elderly patient and one fatal): 2 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1075, 2005-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite